Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Antenatal Bartter syndrome Indication Strategy Report 2026: NKCC2, Trials and Deals
23 July 2026
2026 Antenatal Bartter syndrome strategy: epidemiology, NKCC2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Primary distal renal tubular acidosis Indication Strategy Report 2026: AE1, Trials and Deals
23 July 2026
2026 Primary distal renal tubular acidosis strategy: epidemiology, AE1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Congenital anomalies of kidney and urinary tract Indication Strategy Report 2026: RET, Trials and Deals
23 July 2026
2026 Congenital anomalies of kidney and urinary tract strategy: epidemiology, RET biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Immunotactoid glomerulopathy Indication Strategy Report 2026: CD20, Trials and Deals
23 July 2026
2026 Immunotactoid glomerulopathy strategy: epidemiology, CD20 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Congenital nephrotic syndrome Indication Strategy Report 2026: NPHS1, Trials and Deals
23 July 2026
2026 Congenital nephrotic syndrome strategy: epidemiology, NPHS1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Fibrillary glomerulonephritis Indication Strategy Report 2026: DNAJB9, Trials and Deals
23 July 2026
2026 Fibrillary glomerulonephritis strategy: epidemiology, DNAJB9 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Dense deposit disease Indication Strategy Report 2026: Complement C3, Trials and Deals
23 July 2026
2026 Dense deposit disease strategy: epidemiology, Complement C3 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Steroid-resistant nephrotic syndrome Indication Strategy Report 2026: APOL1, Trials and Deals
23 July 2026
2026 Steroid-resistant nephrotic syndrome strategy: epidemiology, APOL1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Cardiac allograft vasculopathy Indication Strategy Report 2026: mTOR, Trials and Deals
23 July 2026
2026 Cardiac allograft vasculopathy strategy: epidemiology, mTOR biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Inappropriate sinus tachycardia Indication Strategy Report 2026: HCN4, Trials and Deals
23 July 2026
2026 Inappropriate sinus tachycardia strategy: epidemiology, HCN4 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Postural orthostatic tachycardia syndrome Indication Strategy Report 2026: HCN4, Trials and Deals
23 July 2026
2026 Postural orthostatic tachycardia syndrome strategy: epidemiology, HCN4 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Takotsubo cardiomyopathy Indication Strategy Report 2026: Beta-1 adrenergic receptor, Trials and Deals
23 July 2026
2026 Takotsubo cardiomyopathy strategy: epidemiology, Beta-1 adrenergic receptor biology, clinical competition, recent deals, unmet need and market attractiveness.